ROLE OF INTERLEUKIN-6 IN THE PATHOGENESIS OF MULTIPLE MYELOMA

Multiple myeloma (MM) is a currently incurable disease caused by the proliferation of malignant plasma cells. Although the pathogenesis of the disease still remains unclear, recent research in the biology of MM has produced new insights into the factors that control the growth and survival of myelom...

Full description

Saved in:
Bibliographic Details
Published in:Cell biology international 2000-04, Vol.24 (4), p.195-209
Main Authors: Gadó, Klara, Domján, Gyula, Hegyesi, Hargita, Falus, András
Format: Article
Language:English
Subjects:
adhesion molecules
AIDS/HIV
apoptosis
Cell Adhesion Molecules - physiology
Cytokines - physiology
Genes, Tumor Suppressor
Herpesvirus 8, Human - physiology
Histamine - physiology
Humans
interleukin-6
Interleukin-6 - physiology
interleukin-6 receptor
multiple myeloma
Multiple Myeloma - pathology
Multiple Myeloma - physiopathology
Multiple Myeloma - therapy
Oncogenes
pathogenesis
Plasma Cells - cytology
Plasma Cells - physiology
plasmacytoma
Prognosis
Receptors, Interleukin-6 - physiology
Signal Transduction
therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multiple myeloma (MM) is a currently incurable disease caused by the proliferation of malignant plasma cells. Although the pathogenesis of the disease still remains unclear, recent research in the biology of MM has produced new insights into the factors that control the growth and survival of myeloma cells. Among the growth factors, interleukin-6 (IL-6) has an essential role. Evidence suggests that IL-6 is not only a growth factor, but also a survival factor in MM, inhibiting apoptosis in myeloma cells. IL-6 interacts with several factors which are involved in the pathogenesis of MM, such as adhesion molecules, tumour suppressor genes and oncogenes. Considering the essential role of IL-6, it could serve as a target for new therapeutic interventions. Neutralizing the effect of IL-6 may result in a regression of tumour progression.
ISSN:1065-6995
1095-8355
DOI:10.1006/cbir.2000.0497